Endo wrapping up Indevus tender; WHO, Schering in deal for vaccine technology;

> Endo Pharmaceuticals said that Indevus Pharmaceutical stockholders have tendered 61 million shares, or about 78 percent of the company; to wrap up the rest, it plans to make a follow-up offer expiring Friday. Report

> The World Health Organization said Tuesday that a deal with Schering-Plough will allow it to provide poor countries with improved vaccine-making technology to prepare for a possible flu pandemic. Report

>The FDA approved "deep brain stimulation" for the treatment of intractable obsessive-compulsive disorder, or OCD; it's the first time that surgically implanted electrodes have been approved for use in a psychiatric condition. Report

> Medtronic agreed to pay at least $1.03 billion to buy two closely held makers of replacement heart valves that don't require major surgery, taking the medical-device maker into a nascent market and fueling a rivalry with Edwards Lifesciences Corp. Report

> Pfizer is ending development of two medicines that had been in final human testing--one for fibromyalgia and another for generalized anxiety disorder--in order to shift funding to other experimental drugs with more potential. Report

> Swiss biotech group Basilea filed a claim against U.S. partner Johnson & Johnson over delays in launching an antibiotic to treat drug-resistant superbugs after the approval process hit a setback in Europe. Report

> AstraZeneca launched Seroquel XR for acute treatment of bipolar depression, as well as its previous indications for manic and mixed episodes. Release

> Pharma benefits manager Medco Health Solutions posted a 32 percent hike in fourth-quarter profits on growth of mail-order sales and increased demand for higher-margin generics. Report

> David Mott, non-executive director of biopharmaceutical giant Shire has topped up his stake in the company through a purchase of American Depositary Receipts (ADRs). Report

> Cell Therapeutics struck a deal to sell its remaining 50 percent stake in the cancer drug Zevalin for $18 million as it struggles to avoid running out of cash. Spectrum Pharmaceuticals--which already owns half of the drug--bought the remaining rights. Report

> CV Therapeutics has once again spurned a takeover offer from Astellas Pharma--which has done nothing to blunt the Japanese company's interest in a takeover. Report

> Eli Lilly and Daiichi Sankyo have won European approval for their blood thinner Prasugrel, one of the most closely watched therapies in late-stage development. Report

> With its stock tanking on the news that a late-stage trial of its lead drug had failed, the UK's Intercytex got a boost this morning with its announcement that it is reviewing all of its options. Report

> In what could prove to be a major breakthrough, a small "family" of monoclonal antibodies has proven effective in guarding against a range of Type A influenza strains, including the dread H5N1 flu viruses, according to an elite team of U.S. researchers. Report

> The quest for a new obesity drug took a big step forward with new research from Germany demonstrating how a drug that knocks out the FTO 'obesity gene' could help slim down the world's growing population of obese patients. Report

And Finally.. A handful of biotech companies are racing to market a new generation of tests for Down syndrome. Report

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.